Clinical trial
A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension
NCT00461903 is registered in ClinicalTrials.gov with Montreal Heart Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension
- Lead sponsor
- Montreal Heart Institute
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- September 30, 2015
- Enrollment
- 316 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.